Tarsus Pharmaceuticals Inc
NASDAQ:TARS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.61
54.41
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc
Interest Income Expense
Tarsus Pharmaceuticals Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
|
Interest Income Expense
$7.6m
|
CAGR 3-Years
242%
|
CAGR 5-Years
203%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Interest Income Expense
$745m
|
CAGR 3-Years
19%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Interest Income Expense
-$984m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Interest Income Expense
$859m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Interest Income Expense
-$984m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Interest Income Expense
-$426.9m
|
CAGR 3-Years
-100%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-36%
|
|
Tarsus Pharmaceuticals Inc
Glance View
Tarsus Pharmaceuticals Inc. emerged as a dynamic player in the biotech landscape, primarily driven by its innovative approach to addressing unmet medical needs in ocular health. The company gained attention for its work on developing therapeutic solutions for conditions with significant market potential but limited existing treatments. With a focused approach on tackling Demodex blepharitis, an inflammation of the eyelids caused by a common parasitic mite, Tarsus developed TP-03, an innovative product spearheading its advancement in ocular therapeutics. This biopharmaceutical firm's strategy revolves around capitalizing on its scientific expertise to create niche products that cater to specific, underserved segments, aiming for leadership in targeted therapeutic areas. Tarsus Pharmaceuticals relies on the successful commercialization of its treatments to generate revenue, which primarily comes from sales and partnerships. By shepherding its products through clinical trials and securing regulatory approvals, Tarsus positions itself competitively in the pharmaceutical market. Its business model is centered on developing specialized treatments that fill gaps overlooked by larger pharmaceutical companies, allowing it to carve out a unique space in the industry. Furthermore, by building strategic alliances and leveraging partnerships, Tarsus enhances its capabilities for broader distribution and market penetration, thus ensuring sustainable growth and fostering innovation in therapeutic solutions.
See Also
What is Tarsus Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
7.6m
USD
Based on the financial report for Dec 31, 2023, Tarsus Pharmaceuticals Inc's Interest Income Expense amounts to 7.6m USD.
What is Tarsus Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
203%
Over the last year, the Interest Income Expense growth was 1 340%. The average annual Interest Income Expense growth rates for Tarsus Pharmaceuticals Inc have been 242% over the past three years , 203% over the past five years .
You don't have any saved screeners yet
